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(IHC) Assays in Clinical IHC Laboratories
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Abstract: Validation of immunohistochemistry (IHC) assays is a
subject that is of great importance to clinical practice as well as
basic research and clinical trials. When applied to clinical practice
and focused on patient safety, validation of IHC assays creates
objective evidence that IHC assays used for patient care are “ﬁt-
for-purpose.” Validation of IHC assays needs to be properly in-
formed by and modeled to assess the purpose of the IHC assay,
which will further determine what sphere of validation is required,
as well as the scope, type, and tier of technical validation. These
concepts will be deﬁned in this review, part 3 of the 4-part series
“Evolution of Quality Assurance for Clinical Immunohisto-
chemistry in the Era of Precision Medicine.”
Key Words: biomarkers, quality assurance, quality control,
technical validation, revalidation, immunohistochemistry
(Appl Immunohistochem Mol Morphol 2017;25:151–159)
In the last decade, the development of precision medicineand the high throughput discovery methods that support it
have led to increasing use of selective biomarkers for diag-
nosis, prognosis, and prediction of response to targeted
therapy.1–17 This has also led to increasingly stringent criteria
for establishing and monitoring of test performance char-
acteristics in biomarker testing, and has improved processes
for validating methods that are used to detect and measure
these biomarkers.18 The American Association for Cancer
Research (AACR), Food and Drug Administration (FDA),
and National Cancer Institute (NCI) formed the AACR-
FDA-NCI Cancer Biomarkers Collaborative to accelerate
the translation of novel cancer therapeutics into the clinic.18
The AACR-FDA-NCI consensus recommendations were
designed to advance the use of biomarkers in cancer drug
development, the harmonization of biomarker validation
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and the development of reference standards and best prac-
tices for analytical validation.18
Immunohistochemistry (IHC) is an in situ immuno-
assay that detects targeted biomarkers in tissue samples. The
role of IHC in clinical practice has become increasingly di-
verse and the advent of companion diagnostic testing to
support precision medicine has only accelerated that
trend.12,19–22 Similarly, its role in research has become in-
creasingly important in the support of basic research and
discovery and its translation to clinical practice through pre-
clinical and clinical trials. IHC has many characteristics that
make this assay both widely used and highly appreciated:
 its in situ nature enables detection of protein
expression/distribution in diﬀerent tissues, cell pop-
ulations and in cell compartments;
 it can be highly sensitive and speciﬁc;
 it can be multiplexed;
 it is inexpensive, fast, and can be automated.
The most important challenges of the method are:
 it does not generate any results without human readout;
 its results are mostly descriptive;
 preanalytical conditions, essential to the outcomes of
the testing, can be diﬃcult to control or standardize
in the clinical setting, where neither ischemic time
nor conditions of ﬁxation can necessarily be the
same at all times.
This paper builds upon recently issued guidelines
for validation of antibodies and clinical IHC assays,
supports recommendations for the research use of bio-
markers in clinical trials of anticancer drugs and oﬀers a
novel approach to our understanding of validation and
veriﬁcation for clinical applications of IHC. Although
this paper describes concepts that are focused on IHC
methodology, the principles are also immediately appli-
cable to other in situ, cell-based assays.
TERMINOLOGY AND DEFINITIONS
Proper terminology is essential for deﬁning vali-
dation in the context of IHC testing and describing how
validation needs to be planned and executed. The most
important deﬁnitions and clariﬁcations relevant to IHC
validation are:
(1) Deﬁnition of “validation” for IHC testing.
(2) Deﬁnition of “veriﬁcation” for IHC testing.
(3) Characteristics of IHC validation.
(4) Critical components of the IHC test.
(5) Who initiates and who performs the validation?
(6) The role of external quality assurance (EQA) in
validation.
(7) The role of comparison with non-IHC methodologies
for IHC validation.
(8) Planning of Technical Validation of IHC testing
Definition of Validation of IHC Testing
Validation is deﬁned as “conﬁrmation, through the
provision of objective evidence, that requirements for a
speciﬁc intended use or application have been fulﬁlled”
(ISO 9000).23 “Intended use” or “intended application”
are synonymous with “purpose.”
Provision of “objective evidence” is fulﬁlled by col-
lecting evidence that the relevant test performance charac-
teristics (TPCs) have been identiﬁed and assessed.
Validation provides a “high degree of assurance” that these
needs will be met (adapted from the Guideline on General
Principles of Process Validation).24–26
 Purpose: the ﬁrst step in validation is establishing the
purpose of the IHC test in question. The purpose is
critically informed by the needs of the user. Consid-
eration must also be given to whether or not the
proposed IHC test is the appropriate one for this
purpose. The parameters used in constructing the
validation of an IHC test will determine whether that
test is appropriate for its purpose (ﬁt-for-purpose).
Certain IHC tests are declared ﬁt-for-purpose by
regulatory agencies (The US FDA, among many
others—see table 3 in part 1 of the Evolution series)
after considering various types of evidence in the
approval process.27–30 For laboratory developed tests
(LDTs), evidence of whether a given IHC test is fit-for-
purpose may be found in published literature in the
form of diagnostic validation of specific marker(s) or
clinical validation of a biomarker in clinical trials,31,32
as both reasonably require the prerequisite develop-
ment and technical validation of an assay using the
antibody intended for that use.
 Objective evidence: validation of testing requires
planning for how to create objective evidence that a
test will reproducibly meet the needs of the user. In
clinical IHC testing, similar to any other laboratory
test, this evidence is obtained from evaluation and
documentation of TPCs.7,33,34 For TPCs relevant to
IHC testing, see part 2 of the Evolution series.
 Level of assurance: the level of assurance that the needs
of the user will be met is generally deﬁned as “high
degree of assurance” and relates to test accuracy. In
practical terms, it refers to EQA accuracy and/or non-
IHC methodology (NIM) accuracy (see part 2 of the
Evolution series for deﬁnitions) and can be statistically
deduced from the performance of the IHC assay
against the known comparator. It is on this basis that
the CAP Quality Center recommended the use of at
least 20 cases with known positive or negative results in
a technical validation set for a given type 1-IHC assay
(assuming speciﬁc validation guidelines do not already
exist), arguing that a suﬃciently “high degree of
assurance” (based on 95% conﬁdence intervals) are
achieved with agreements of Z90% between actual
and expected values35 The level of assurance (or
accuracy) for a particular IHC test, has in some
instances already been speciﬁcally addressed by pro-
fessional organizations. Examples of the latter include
the agreement of Z95% with alternative validated
method or same validated method for HER2.26
Definition of Verification of IHC Testing
Veriﬁcation is deﬁned as “conﬁrmation, through the
provision of objective evidence, that speciﬁed require-
ments have been fulﬁlled” (ISO 9000).23
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Veriﬁcation requires conﬁrmation that pre-
determined speciﬁcations are consistently met, meaning
that the test, an analyte or other IHC test component
performs as expected from a technical perspective or that
the laboratory is performing an already established test
correctly. “Established” refers to those tests that were
previously either diagnostically and/or clinically validated
for a speciﬁc purpose. In other words, veriﬁcation con-
ﬁrms that the reagents supplied and the protocols used
yield the appropriate analytical sensitivity, speciﬁcity, and
reproducibility. In the “ﬁt-for-purpose” framework, ver-
iﬁcation of an IHC assay is tier 1 technical validation (see
below tiers of validation).
All IHC kits cleared or approved by the FDA and
other regulatory agencies need to be veriﬁed before being
put into clinical use, because while the supplier can pro-
vide proof that the kit is designed and performing well if
properly used, the supplier cannot ensure that the labo-
ratory performing the test will actually properly use the
kit. Therefore, the manufacturer is responsible for vali-
dation (manufacturer provides evidence that the test they
are selling is appropriate test for the condition to be
demonstrated), but not for veriﬁcation. Veriﬁcation or
demonstration that a validated test is achieving the de-
sired analytical sensitivity, speciﬁcity, and reproducibility
is the responsibility of the laboratory performing the test.
If the manufacturer/supplier provides exact instructions
and tools for veriﬁcation, they should be followed.
Characteristics of Validation
Validation can only be properly designed for any
given IHC assay after all characteristics of validation are
considered in the planning stage. There are 4 character-
istics of validation: sphere, scope, type, and tier.
 Spheres of validation: there are 3 spheres of validation:
technical, diagnostic, and clinical. Clinical IHC labo-
ratories typically perform only technical validation.
Therefore, the rest of the article will refer to technical
validation unless otherwise stated. In principal,
“technical validation” is required for all IHC tests
(whether they are applied to investigational or clinical
questions) and it is the IHC laboratory that performs
technical validation of these protocols. Although
clinical IHC laboratories generally do not perform
“diagnostic validation” or “clinical validation” of IHC
tests, evidence for diagnostic validation or clinical
validation is required for all tests that will be
performed in the clinical IHC laboratory. Such
evidence is usually available in peer-reviewed published
literature. Neither CLIA’88 nor CAP requires clinical
or diagnostic validation to be done by the IHC
laboratory before clinical implementation of an IHC
assay. Therefore, reliance on the evidence of diagnostic
and clinical validations in published peer-reviewed
literature is appropriate.
 Scope of technical validation: scope of technical
validation (or validation of the analytical phase of
IHC testing) includes initial validation and (when
appropriate) revalidation. Initial validation is required
when a test is ﬁrst introduced as well as when a new
purpose is articulated for an already validated test.
Revalidation is required when: (1) there is a change in a
critical test component (primary revalidation; for the
deﬁnition of “critical test components” see below); (2)
when there is a change in a test performance character-
istic that occurred without any change to critical test
components (secondary revalidation); and (3) when there
is a change in noncritical test components only (tertiary
revalidation). This is summarized in Table 1. One of the
most common reasons for primary revalidation is a
change in the primary antibody. For example, for a CD3
IHC test that has been validated for detection of T-cell
diﬀerentiation with a monoclonal antibody that is no
longer commercially available, the introduction of a new
monoclonal or polyclonal anti-CD3 antibody requires
primary revalidation because the test is now functionally
an entirely new assay, irrespective of its commercial
name. When the supplier has changed, but the primary
antibody is of the same clone, only tertiary revalidation
is required. So that these changes are transparent to the
end user, both the laboratory test method and the
pathology reports that detail the readout and interpre-
tation of that test, diﬀerent clones and diﬀerent
polyclonal antibodies should be referred to by both
their clone name (or generic name for a the polyclonal
antibody), and by their molecular target. Although using
gene names may appear to be universally acceptable,
antibodies are developed for the proteins and, on
occasion, gene name may be less informative (eg,
antibodies for phosphorylated proteins or mutated gene
products).36–38 Epitopes detected by diﬀerent antibodies
may have diﬀerent performance characteristics related to
preanalytical parameters. Some CD3 epitopes may be
resistant to prolonged cold ischemic times, while others
may degrade very quickly after devitalization. Some
epitopes signiﬁcantly change during ﬁxation and embed-
ding and may not be recovered to the same degree as
others with a given antigen retrieval protocol.39–42 In
principle, IHC assays based on diﬀerent antibodies
against a common target (such as CD3) are diﬀerent
assays that must be validated separately before their
introduction to clinical testing.35 Recognition that there
is a need for primary revalidation is particularly
important for type 2-IHC tests [eg, estrogen receptor
(ER) for breast cancer, anaplastic lymphoma kinase for
lung cancer, etc.]. If a new clone for ER for breast cancer
or anaplastic lymphoma kinase for lung cancer is
introduced for clinical use in the laboratory that is
already using some other ER or anaplastic lymphoma
kinase clone, this is another example that represents a
change in a critical test component and thus requires
primary revalidation. In contrast, secondary revalidation
is required when there is observed change in any of the
relevant test performance characteristics; these may
occur either due to reproducible change in results with
on-slide controls or suboptimal results in proﬁciency
testing (PT) (the latter only if there is evidence of
previous success in PT by using the same protocol).
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 Type of technical validation: when the term
“validation” is used, it is essential to be speciﬁc about
what is being validated as this deﬁnes what type of
technical validation is being performed. In IHC,
validation may refer to: generic validation of primary
antibody, validation of the same clone from a diﬀerent
supplier, lot-to-lot primary antibody validation, vali-
dation of buﬀers, diluents, visualization system, and
other reagents, validation of equipment, validation of
preanalytical conditions (ﬁxative, ﬁxation time, decal-
cifying reagents, decalciﬁcation time, etc.), validation
of controls, technical validation of IHC protocols of
biomarkers, and validation of IHC readout.5,43 This
series addresses speciﬁcally 2 types of validation: (i)
technical validation of IHC protocols of biomarkers
(Fig. 1), and (ii) validation of the IHC readout (Fig. 2).
 Tiers of technical validation: tiers of technical validation
relate to TPCs included in validation. Technical
validation spans from tier 1 to tier 3. Tier 3 validation
(full validation) consists of determining analytical
sensitivity and speciﬁcity, analytical reproducibility,
demonstration of reportable range, determining desired
(predetermined) high level of accuracy within reportable
range, determining protocol preanalytical robustness,
and determining readout accuracy and precision where
applicable. Figure 1 summarizes all 3 tiers of technical
validation of the IHC protocol. Validation of the entire
analytical phase is completed by inclusion of validation
of the readout (Fig. 2). The tissue tools required for
diﬀerent tiers of validation are described in part 4 of the
Evolution series. Ideally, all IHC tests performed by an
accredited clinical laboratory for patient care should
have evidence of tier 3 validation; however, this is not
always possible. Evidence gathered in tier 2 validation is
essential for clinical applications of all IHC tests and
applies to initial validation of IHC LDTs.
Critical Components of the IHC Test
IHC is a complex process, the results of which are
inﬂuenced by multiple parameters in the preanalytical,
analytical, and postanalytical test phases. Potential crit-
ical components in all of these steps must be identiﬁed and
deﬁned based on published evidence along with cumu-
lative clinical and EQA experience. Deﬁning the critical
components of clinical laboratory tests is important be-
cause if changes are made to any critical component of an
already validated IHC test, then primary revalidation of
the IHC test needs to be performed. This is why “in-
house” changes to an FDA (or other regulatory agency)
cleared or approved IHC test automatically transform it
into a LDT and, as such, the test no longer carries the
imprimatur of the regulatory agency.42 Similarly, in-
troducing changes to an already validated LDT requires
consideration regarding the need for possible revalidation.
(a) Preanalytical phase: While the preanalytical phase is
diﬃcult to control, it is reasonably well-deﬁned and
its importance is generally agreed upon.44–48 There
are numerous components in the preanalytical
phase.48 Of these, a subset can be identiﬁed for which
changes would automatically trigger the need for
primary revalidation of the IHC protocol. The critical
components of the preanalytical phase include: (1)
ﬁxative type, (2) decalcifying reagent type, and (3)
instrumentation for tissue processing. Any change in
other preanalytical components (ie, noncritical com-
ponents), while it may not automatically trigger the
need for primary revalidation, may still ultimately
require secondary or tertiary revalidation if the
noncritical component change leads to unacceptable
alterations in test performance characteristics.
(b) Analytical phase: Because of intricacies related to its
in situ, cell-based, descriptive nature, as well as the
dual role of the pathologist (readout and interpreta-
tion), the components of the analytical phase of the
IHC test are complex and are not immediately self-
evident. The analytical phase for formalin-ﬁxed/
paraﬃn-embedded tissues consists of four major
components: (1) antigen retrieval method, (2) primary
antibody, (3) detection system, and (4) readout
(Fig. 3). Although there are other components of
the analytical phase, it is any of these four critical
components that will necessitate primary revalidation
of the IHC protocol if they are changed. When
critical components (1), (2), and (3) are combined,
they are synonymous with “IHC protocol.”49 The
addition of component 4 (readout) completes the
analytical phase (see part 1 from Evolution series)
(Fig. 2). Although ultimately the IHC slides will be
sent to pathologists for readout and interpretation,
the design of the readout validation is under the
purview of the IHC laboratory medical director who
ensures that readout methods are deﬁned and align
with the purpose of the test. Any change in other
analytical components (ie, noncritical components),
while it may not automatically trigger the need for
primary revalidation, may still ultimately require
secondary or tertiary revalidation if the noncritical
component change leads to unacceptable alterations
in monitored test performance characteristics.
TABLE 1. Scope of Technical Validation
Scope Trigger Tiers
Initial New test or new purpose Tier 2 or 3
Revalidation (no new purpose)
Primary Change in critical test
components (±change
in TPCs)
Tier 2 or 3
Secondary Change in TPCs, but no
change in critical test
components
Tier 1 for type
1-IHC
Tier 2 for type
2-IHC
Tertiary Change in noncritical test
components only (eg,
changes in primary Ab
dilution)
Tier 1
Ab indicates antibody; IHC, immunohistochemistry; TPCs, test performance
characteristics.
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(c) Postanalytical phase: The postanalytical phase includes
interpretation of the readout by the end user for a
particular intended use. This is where the “use” of the
test results should align with the “purpose” for which
the test was validated. If the use of the test results is not
linked to the purpose for which the test was originally
validated, then initial validation needs to be performed
to determine whether the current IHC protocol can
fulﬁll the new purpose (see part 1 of the Evolution
series), or whether a new IHC protocol needs to be
developed and validated for the new purpose. The use
may be altered by either pathologists (for type 1-IHC
tests) or by the treating physician (for type 2-IHC
tests). In such situations, by changing the use of the
test, the end user is eﬀectively relying on an
unvalidated IHC testing the same way that a treating
physician is using an “unvalidated” clinical manage-
ment plan by administering a medical therapy “oﬀ-
label.” It is important to recognize that such a decision
with respect to change of “use” of an IHC test may be
unknown to the laboratory and thus, the responsibility
to initiate validation lies with the end user (pathologist
or oncologist).
Who Initiates and Who Performs the
Validation?
The responsibility for the validation of various
components of the IHC test lies with the party that
controls those components. Responsibility for IHC test
Tier 3
Tier 2
Tier 1
( aka. Verification)
Robustness 
(Pre-Analytical)
Pre-Analytical 
Reproducibility 
Analytical 
Reproducibility
Analytical 
Sensitivity 
(LOD)
Basic 
Analytical 
Specificity
Reportable Range
Extended Analytical 
Specificity
Accuracy 
FIGURE 1. Three tiers of validation of the immunohistochemistry protocol. Each tier of technical validation is based on the type of
evidence it provides for the test validation (by including different test performance characteristics). LOD indicates limit of detection.
ANALYTICAL PHASE
Validation of 
Readout 
Accuracy 
+/- Precision
Technical 
Validation of 
IHC Protocol
FIGURE 2. Validation of IHC analytical phase includes vali-
dation of IHC protocol (Fig. 2) as well as validation of the
readout. Readout validation consists of demonstrating that
readout accuracy and readout precision are acceptable for
clinical practice. If image analysis is used as an aid for the
readout, then it also needs validation to demonstrate a desir-
able level of accuracy and precision. IHC indicates im-
munohistochemistry.
Antigen 
Retrieval
Primary 
Antibody
Readout
Detection/Visual
ization
FIGURE 3. “Four squares” of the immunohistochemistry an-
alytical phase, which starts with antigen retrieval (including
“none” as an option) and is completed by the readout.
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validation can be divided into: (i) responsibility for ini-
tiation of IHC test validation, and (ii) responsibility for
design and conducting the IHC test validation.
Responsibility for initiation of validation of various
IHC test components is delegated to their most appropriate
“owner.” The clinical IHC laboratory and its medical di-
rector are responsible for triggering the initial validation of
the analytical phase whenever a new IHC test is being in-
troduced or for triggering revalidation of the IHC protocol
whenever changes in the critical components of the IHC
protocol or its intended use are made, or unacceptable
change in monitored test performance characteristics occurs
as discussed earlier. It must be emphasized that the respon-
sibility for the validation of the readout lies solely with the
medical director of the laboratory. In addition, if a critical
component of an IHC test is being made in areas that are
not controlled by the IHC laboratory, the responsible party
needs to consider the implications of the changes for that
IHC test. This also includes the responsibility of the path-
ologist (other than medical director of IHC laboratory) to
trigger the validation of the IHC test if he/she changes the
readout of the IHC test or the use of the IHC test in such
way that it does not align with the originally validated
purpose of the test. Otherwise, the responsibility for vali-
dation of various IHC test components is as follows:
 purchased reagents need to be validated by the
suppliers who make claims about the reagents
relevant to its “ﬁt-for-purpose” principle;
 purchased or leased equipment needs to be validated
by the suppliers who make claims about the equip-
ment; although clinical laboratories often perform
some sort of veriﬁcation of the new equipment (and
may be helped in this process by the supplier), full
validation of the equipment is done by the supplier;
 “home-made” reagents and equipment need to be
validated by the party that put the “home-made”
reagent/equipment into use;
 initial or changed preanalytical components need to be
validated in collaboration with surgical pathology (ie,
grossing room), histology and the IHC laboratory;
 pathologist interpretation of type 1-IHC tests for
diagnostic use (diagnostic validation of type 1-IHC)
is validated in the published literature and if not
already published, internal diagnostic validation is
required by the pathologist who is using the IHC test
or by the IHC medical director;
 clinical validation for predictive and prognostic
markers is generally published in the literature; this
is typically based on the results of clinical trials and
other clinical studies (or rarely it is established
internally when appropriate follow-up or other
clinical data are available), although not all pub-
lished “clinical validations” meet the rigorous
criteria initially proposed by McGuire;50
 FDA-approved (or other regulatory agency cleared
or approved) IHC kits are already clinically vali-
dated for a speciﬁc purpose; however, veriﬁcation
(tier 1 validation) of these kits remains the respon-
sibility of the IHC laboratory utilizing the kits.
It is clear from the above that the validation of IHC
testing requires a team approach and that the IHC lab-
oratory can only be responsible for validation of the
components of the test over which it has direct control,
though it must be prepared to respond appropriately to
internal evidence that intended use and readout parame-
ters have been or are being modiﬁed in local practice.
The Role of EQA in IHC Validation
EQA has an important role in IHC validation be-
cause it may provide important information about various
IHC TPCs. It can provide an evidentiary basis for IHC test
analytical sensitivity and speciﬁcity (ie, whether the test was
properly calibrated), IHC test accuracy (ie, agreement
of results with designated standard), accordance (ie, the
probability that 2 identical test materials analyzed by the
same laboratory under standard repeatability conditions
will both yield the same result; for example, such that both
are found to be positive or both are found to be negative),
concordance (ie, the probability that 2 identical test mate-
rials sent to diﬀerent laboratories will both yield the same
result).51–54 It can be performed by participation in PT or
by interlaboratory testing as appropriate.55,56 EQA pro-
grams often use a small number of tissue samples that are
immunohistochemistry critical assay performance controls
(iCAPCs) or their equivalent for PT. The results of such PT
challenges usually provide good evidence of analytical
sensitivity and speciﬁcity.15,57–59 Indeed, well-controlled PT
exercises can generate a high level of evidence as a basis for
deﬁning TPCs. EQA programs or interlaboratory testing
that include TMA samples with the suﬃcient number and
proper selection of tissue samples can provide evidence of
test accuracy (EQA accuracy).60,61 When EQA samples
include tissues that have been subjected to various known
preanalytical conditions, they provide evidence of pre-
analytical IHC protocol robustness. Some EQA programs
also provide clinical validation of IHC testing. This is rare,
but it has been accomplished by the German EQA program
(QuIP—Quality in Pathology) for HER2 in gastric cancer
as the PT sample design had been developed by the ToGA
Study – A Study of Herceptin (Trastuzumab) in Combi-
nation With Chemotherapy Compared With Chemo-
therapy Alone in Patients With HER2-Positive Advanced
Gastric Cancer.62
The Role of Comparison With Non-IHC Methods
for IHC Validation
For some IHC tests, comparison with results of
non-IHC methodologies can provide evidence of IHC
protocol accuracy (NIM accuracy; see part 2 of the
Evolution series). The alternative methodology needs to
be assessed as to whether it has been already validated for
the same intended clinical application and whether there
is evidence that it can be considered as the “designated
true value.” The alternative methodology should not be
used for IHC validation if it has not been properly vali-
dated for the same purpose. The comparison can be
performed intralaboratory, interlaboratory, or by partic-
ipation in PT. If the laboratory can internally evaluate
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concordance with non-IHC methodology results, external
validation may not be necessary for tier 2 validation. This
approach is typically used in tier 2 validation for type 2-
IHC tests (eg, HER2 IHC validation by ﬂuorescence
in situ hybridization).26
Planning of Technical Validation for IHC Testing
Validation of IHC testing requires a formal validation
plan, which needs to be completed before operational im-
plementation. At the planning stage, all aspects of technical
validation need to be considered to determine what scope,
type, and tier of validation need to be executed. In other
words, whether it is an initial validation or revalidation that
is required, what is being validated, and which TPCs will be
evaluated for the validation need to be formulated. Fur-
thermore, a “ﬁt-for-purpose” approach requires that any test
be validated for speciﬁc intended use with an identiﬁed end
user, as well as identiﬁed needs of the end user. This planning
and preparation also involves the creation of proper quality
tools (as a component of the laboratory’s quality manage-
ment plan) that will be needed not only for test development,
but also for on-going quality monitoring (see part 4 of the
Evolution series). Table 2 illustrates steps of the planning
stage for initial technical validation. A similar approach may
also be feasible for revalidation.
CONCLUSIONS
 “Validation” provides objective evidence at a high level
of assurance that a test is ﬁt-for-purpose.
 “Validation” should always be used with a qualiﬁer
describing the sphere, scope, type, and tier of
validation.
 ”Veriﬁcation” is synonymous with tier 1 technical
validation.
 “Revalidation” should always be used with a qualiﬁer
describing whether it is primary, secondary, or tertiary
and what trigger prompted the reevaluation.
TABLE 2. Planning of Initial Technical Validation of IHC Testing
Illustrative Examples
Steps That Need Documentation Type 1-IHC (eg, Melan-A) Type 2-IHC (eg, ER)
1. Identify/designate the name of the
test
Melan-A Estrogen Receptor (ER)
2. Identify the purpose of the IHC test* Detection of melanocytic diﬀerentiation Detection of ER expression in breast cancer
3. Identify end user Pathologist Oncologist
4. Identify needs of the end user The need for a highly sensitive and speciﬁc marker of
melanocytic diﬀerentiation at the diagnostic
sensitivity and speciﬁcity demonstrated in published
literature
The need for quantitative marker that will predict
response to tamoxifen at the rate demonstrated in
previously published clinical trials
5. Identify if the marker has been
diagnostically and/or clinically
validatedw
Yes (properly diagnostically validated in published
literature)
Yes (properly clinically validated in published
literature)
6. Identify if there is relevant peer-
reviewed published evidence on
technical validation
No (details of technical validation not available) Yes (details of technical validation available)
7. Select publication(s) that will guide
protocol developmentw
List relevant PubMed or other peer-reviewed
publications
List relevant PubMed or other peer-reviewed
publications
8. Identify if previously validated
primary Ab is available
commerciallyz
Yes (MART-1) or other as relevant Yes (SP-1) or other as relevant
9. Identify if tissues required for test
development and controls are
available
Search revealed that adrenal gland, kidney, strongly
positive malignant melanoma, weakly positive
melanoma, and ovarian granulosa cell tumor are
useful (eg, www.nordiqc.org)
Search in published literature revealed that cervix,
tonsil, and 4 breast carcinomas with graded
predetermined expression range from 0% to 100%
are useful as well as 50 positive and 50 negative
cases of breast carcinoma (eg, www.nordiqc.org,
ASCO/CAP guidelines)
10. Identify what is required for the
new test readoutw
Qualitative assessment by pathologist Qualitative and quantitative assessment by
pathologists; image analysis may be applied
11. Identify appropriate EQA program
or external laboratory and/or non-
IHC method for tier 2 validation
EQA program that provides Melan-A challenges or
any laboratory with demonstrated success in EQA
testing for Melan-A (laboratories with expertise in
melanoma diagnostics are preferred); could be used
for EQA accuracy
EQA program that provides PT samples for ER
challenges or designated reference laboratory for
ER; if PT samples contain suﬃcient number of
breast carcinoma cases, they may be used for EQA
accuracy
12. Develop tools for test development
and on-going quality monitoring
See part 4 of Evolution Series
Develop iCAPCs, Index and Accuracy TMA for type
1-IHC
See part 4 of Evolution Series
Develop iCAPCs, Index and Accuracy TMA for type
2-IHC
*It is assumed that the purpose is clinically justiﬁable.
wIf the marker has not been diagnostically and/or clinically validated, the laboratory cannot use the test or the laboratory needs to perform full diagnostic and/or
clinical validation as appropriate; IHC medical director or pathologist(s) that request new test development should provide relevant publications.
zIf primary antibody is not commercially available or tissues are not available, it may not be possible to develop proper test.
Ab indicates antibody; ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; ER, estrogen receptor; EQA, external quality assurance;
IHC, immunohistochemistry; iCAPCs, immunohistochemistry critical assay performance controls; PT, proﬁciency testing.
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 The IHC laboratory is responsible for technical
validation of all IHC tests that are performed in the
IHC laboratory and must be prepared to produce
objective evidence of test performance (ie, by evaluat-
ing relevant test performance characteristics) at the
relevant levels of assurance (as suggested by profes-
sional organizations or accrediting bodies).
 Planning of technical validation starts with the consid-
eration of what scope, type, and tier of validation need
to be executed.
 Use the same primary antibodies that have previously
been found to be “ﬁt-for-purpose” and introduce/
develop and technically validate IHC protocols that
can reasonably reproduce results appropriate to pre-
viously published or disseminated diagnostic or clinical
validation studies. If an IHC test has not been properly
diagnostically or clinically validated in published
literature and it will be introduced for diagnostic or
other clinical purposes, the IHC laboratory needs to
perform a diagnostic and/or clinical validation as
appropriate. For most clinical laboratories this is not
possible, so these tests should not be performed.
 The tests that are cleared or approved by the FDA or
other regulatory bodies were already validated for a
speciﬁc purpose and therefore only need veriﬁcation by
the end-user laboratory (tier 1 validation) if a diﬀerent
method of veriﬁcation is not speciﬁcally instructed by the
manufacturer or by professional practice guidelines.
 Comparison with IHC results from PT and/or inter-
laboratory collaboration as well as non-IHC method
results can be used to determine IHC protocol accuracy
and robustness, which are important for tier 2 validation.
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